Author:
Hannah J. S.,Bodkin N. L.,Paidi M. S.,Anh-Le N.,Howard B. V.,Hansen B. C.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference41 articles.
1. Ambrogi V, Cozzi P, Sanjust P, Bertone L, Lovisolo PP, Briatico-Vangosa G, Angelucci R, Antilipolytic activity of a series of pyrazine-N-oxides. Eur J Med Chem 15:157–163, 1980
2. Lovisolo PP, Briatico-Vangosa G, Orsini G, Ronchi R, Angelucci R, Valzelli G, Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (Acipimox) 1. Mechanism of action. Pharm Res Commun 13: 151–162, 1981
3. Sirtori CR, Gianfranceschi G, Sirtori M, Berini F, Descovich G, Montaguti U, Fuccella LM, Musatti L, Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with Acipimox, a new inhibitor of lipolysis. Atherosclerosis 38:267–271, 1981
4. Stirling C, McAleer M, Reckless JPD, Campbell RR, Mundy D, Betteridge DJ, Foster K, Effects of Acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa. Clin Sci 68: 83–89, 1985
5. National Cholesterol Education Program Expert Panel. Report on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 148:36–39, 1988
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献